Rotavirus VP6 preparations as a non-replicating vaccine candidates

Jalilvand, Somayeh; Marashi, Sayed Mahdi; Shoja, Zabihollah

doi:10.1016/j.vaccine.2015.05.026

Cited by 21 publications

(14 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the middle layer protein of rotavirus, VP6 is the main component of viral structure protein, and content for 51% of the total viral protein [10]. Although the protective mechanisms of VP6 have not been completely clarified, it can induce heterotypic cross-protective rotavirus immunity responses and confer protection against rotavirus in animal models [11–13]. Subunit vaccines reduce the risk of side effects such as spontaneous reversions of attenuated vaccines and denaturing of antigenic peptides with inactivated vaccines [14], while the problem is that subunit vaccines in general are not as immunostimulatory as the whole organism vaccines [15], and usually require cholera toxin (CT), CpG or heat-labile enterotoxin (LT) as the adjuvants.…”

Section: Introductionmentioning

confidence: 99%

A milk-based self-assemble rotavirus VP6–ferritin nanoparticle vaccine elicited protection against the viral infection

Cui

Wang

et al. 2019

J Nanobiotechnol

View full text Add to dashboard Cite

BackgroundRotavirus is the leading cause of severe dehydrating diarrhea in young children and the inner capsid protein VP6 is a potential vaccine candidate that can induce cross-protective immune responses against different Rotavirus strains. The use of ferritin nanoparticles as the scaffold of the antigen can improve the immunogenicity of the subunit vaccines and provide broader protection. We here present a non-live and self-assemble recombinant rotavirus VP6–ferritin (rVP6–ferritin) nanoparticle vaccine.ResultsThe rVP6–ferritin nanoparticles were expressed in E. coli and self-assembled to uniform spherical structure which similar to ferritin, and oral administration of them induced efficient humoral and mucosal immunogenicity in mice. The nanoparticles were further transgenically expressed in the milk of mice, and pup mice breastfed by transgenic rVP6–ferritin mothers had strongly induced immunogenicity and—compared to pups breastfed by wild type mothers—the proportion of rotavirus challenged pups with diarrhea symptoms, the duration and intensity of the diarrhea, and the deleterious effects on overall growth resulting from the diarrhea were all significantly reduced.ConclusionsThese results suggest that this recombinant VP6–ferritin nanoparticle vaccine can efficiently prevent the death and malnutrition induced by the rotavirus infection in infants and is a promising candidate vaccine for rotavirus.Electronic supplementary materialThe online version of this article (10.1186/s12951-019-0446-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

A milk-based self-assemble rotavirus VP6–ferritin nanoparticle vaccine elicited protection against the viral infection

Cui

Wang

et al. 2019

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…For this group, several studies have pointed out that the VP6 protein confers protection against infection in some animal models, despite not inducing neutralizing antibodies. In particular, Jalilvand et al (2015) have excellently summed up the main contributions of different groups that have worked with the VP6 protein of RVA as an immunogen. Also, recent publications have used VP6 protein as an immunogen proposed for vaccine development against RVA following different strategies (Feng et al, 2017;Afchangi et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the immunogenicity of a recombinant HSV-1 vector expressing human group C rotavirus VP6 protein

Rota

Palacios

Temprana

et al. 2018

Journal of Virological Methods

View full text Add to dashboard Cite

Group C Rotavirus (RVC) has been associated globally with sporadic outbreaks of gastroenteritis in children and adults. RVC also infects animals, and interspecies transmission has been reported as well as its zoonotic potential. Considering its genetic diversity and the absence of effective vaccines, it is important and necessary to develop new generation vaccines against RVC for both humans and animals. The aim of the present study was to develop and characterize an HSV-1-based amplicon vector expressing a human RVC-VP6 protein and evaluate the humoral immune response induced after immunizing BALB/c mice. Local fecal samples positive for RVC were used for isolation and sequencing of the vp6 gene, which phylogenetically belongs to the I2 genotype. We show here that cells infected with the HSV[VP6C] amplicon vector efficiently express the VP6 protein, and induced specific anti-RVC antibodies in mice immunized with HSV[VP6C], in a prime-boost schedule. This work highlights that amplicon vectors are an attractive platform for the generation of safe genetic immunogens against RVC, without the addition of external adjuvants.

show abstract

“…Since VP6 is highly conserved within the same RV group, it can confer heterotypic protection [ 21 , 22 ]. The use of VP6 as a possible candidate vaccine as well as the plausible mechanisms behind the VP6-induced protection have been extensively reviewed by Ward et al, 2010 and Jalilvand et al, 2015 [ 23 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

Rotavirus VP6 protein mucosally delivered by cell wall-derived particles from Lactococcus lactis induces protection against infection in a murine model

Temprana¹,

Argüelles²,

Gutierrez³

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

Rotaviruses are the primary cause of acute gastroenteritis in children worldwide. Although the implementation of live attenuated vaccines has reduced the number of rotavirus-associated deaths, variance in their effectiveness has been reported in different countries. This fact, among other concerns, leads to continuous efforts for the development of new generation of vaccines against rotavirus.In this work, we describe the obtention of cell wall-derived particles from a recombinant Lactococcus lactis expressing a cell wall-anchored version of the rotavirus VP6 protein. After confirming by SDS-PAGE, Western blot, flow cytometry and electronic immunomicroscopy that these particles were carrying the VP6 protein, their immunogenic potential was evaluated in adult BALB/c mice. For that, mucosal immunizations (oral or intranasal), with or without the dmLT [(double mutant Escherichia coli heat labile toxin LT(R192G/L211A)] adjuvant were performed. The results showed that these cell wall-derived particles were able to generate anti-rotavirus IgG and IgA antibodies only when administered intranasally, whether the adjuvant was present or not. However, the presence of dmLT was necessary to confer protection against rotavirus infection, which was evidenced by a 79.5 percent viral shedding reduction.In summary, this work describes the production of cell wall-derived particles which were able to induce a protective immune response after intranasal immunization. Further studies are needed to characterize the immune response elicited by these particles as well as to determine their potential as an alternative to the use of live L. lactis for mucosal antigen delivery.

show abstract

Rotavirus VP6 preparations as a non-replicating vaccine candidates

Cited by 21 publications

References 153 publications

A milk-based self-assemble rotavirus VP6–ferritin nanoparticle vaccine elicited protection against the viral infection

A milk-based self-assemble rotavirus VP6–ferritin nanoparticle vaccine elicited protection against the viral infection

Evaluation of the immunogenicity of a recombinant HSV-1 vector expressing human group C rotavirus VP6 protein

Rotavirus VP6 protein mucosally delivered by cell wall-derived particles from Lactococcus lactis induces protection against infection in a murine model

Contact Info

Product

Resources

About